New drug trial targets stubborn autoimmune blood diseases
NCT ID NCT07175493
Summary
This early-stage study is testing an experimental drug called CM336 in adults whose autoimmune blood disorders have not responded to other treatments. The main goals are to see if the drug is safe and if it can help improve patients' blood cell counts. Researchers will monitor for side effects and measure changes in platelet or hemoglobin levels over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA (ITP) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Blood Disease Hospital, Chinese Academy of Medical Sciences
RECRUITINGTianjin, Tianjin Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Henan Cancer Hospital
RECRUITINGZhengzhou, Henan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Heping Hospital Affiliated to Changzhi Medical College
RECRUITINGChangzhi, Shanxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.